XBiotech: FDA Grants Permission To Begin Trials With XB2001 Therapy In Pancreatic Cancer

XBiotech (XBIT) said the FDA has granted permission to commence clinical trials with its drug candidate for treating patients with pancreatic cancer. The phase I/II study will evaluate the company's new drug candidate when added to the ONIVYDE/5-FU combination therapy.

XBiotech's new drug XB2001 is a naturally occurring antibody. It specifically targets a process potentially involved in the growth and spread of malignant tumors; and the drug also blocks inflammation associated with tissue injury, which may reduce toxicity associated with the chemotherapy.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Google has revoked its three-year ban on cryptocurrency-related ads on its sites under the search giants' new ad services policy. This action will now allow cryptocurrency exchanges and wallets certified by Google to advertise their products and services on Google's network, beginning August 3, 2021. The UK's competition regulator said Friday that it has secured commitments from Google to address concerns about the tech giant's proposal to remove third-party cookies from Chrome browser. Archer Aviation, a developer of electric vertical take-off and landing or eVTOL aircraft, unveiled its autonomous electric two-seater aircraft, named "Maker", marking a milestone towards its commercial launch. The California-based air mobility company, which has already received orders from United Airlines, will use its inaugural aircraft prototype for testing as it works towards certification.
Follow RTT